168 related articles for article (PubMed ID: 26301626)
21. Isoform-specific phosphoinositide 3-kinase inhibitors exert distinct effects in solid tumors.
Edgar KA; Wallin JJ; Berry M; Lee LB; Prior WW; Sampath D; Friedman LS; Belvin M
Cancer Res; 2010 Feb; 70(3):1164-72. PubMed ID: 20103642
[TBL] [Abstract][Full Text] [Related]
22. Discovery of oral and inhaled PDE4 inhibitors.
Ting PC; Lee JF; Kuang R; Cao J; Gu D; Huang Y; Liu Z; Aslanian RG; Feng KI; Prelusky D; Lamca J; House A; Phillips JE; Wang P; Wu P; Lundell D; Chapman RW; Celly CS
Bioorg Med Chem Lett; 2013 Oct; 23(20):5528-32. PubMed ID: 24018187
[TBL] [Abstract][Full Text] [Related]
23. Discovery of novel oxazolidinedione derivatives as potent and selective mineralocorticoid receptor antagonists.
Yang C; Shen HC; Wu Z; Chu HD; Cox JM; Balsells J; Crespo A; Brown P; Zamlynny B; Wiltsie J; Clemas J; Gibson J; Contino L; Lisnock J; Zhou G; Garcia-Calvo M; Bateman T; Xu L; Tong X; Crook M; Sinclair P
Bioorg Med Chem Lett; 2013 Aug; 23(15):4388-92. PubMed ID: 23777778
[TBL] [Abstract][Full Text] [Related]
24. A selective matrix metalloprotease 12 inhibitor for potential treatment of chronic obstructive pulmonary disease (COPD): discovery of (S)-2-(8-(methoxycarbonylamino)dibenzo[b,d]furan-3-sulfonamido)-3-methylbutanoic acid (MMP408).
Li W; Li J; Wu Y; Wu J; Hotchandani R; Cunningham K; McFadyen I; Bard J; Morgan P; Schlerman F; Xu X; Tam S; Goldman SJ; Williams C; Sypek J; Mansour TS
J Med Chem; 2009 Apr; 52(7):1799-802. PubMed ID: 19278250
[TBL] [Abstract][Full Text] [Related]
25. Anti-inflammatory actions of Chemoattractant Receptor-homologous molecule expressed on Th2 by the antagonist MK-7246 in a novel rat model of Alternaria alternata elicited pulmonary inflammation.
Gil MA; Caniga M; Woodhouse JD; Eckman J; Lee HH; Salmon M; Naber J; Hamilton VT; Sevilla RS; Bettano K; Klappenbach J; Moy L; Correll CC; Gervais FG; Siliphaivanh P; Zhang W; Zhang-Hoover J; McLeod RL; Cicmil M
Eur J Pharmacol; 2014 Nov; 743():106-16. PubMed ID: 25261040
[TBL] [Abstract][Full Text] [Related]
26. Crystalline forms of 2,2,2-trifluoro-N-[(1R,2S)-1-{[1-(4-fluorophenyl)-1H-indazol-5-yl]oxy}-1-(3-methoxyphenyl)-2-propanyl]acetamide (AZD-5423).
Norman P
Expert Opin Ther Pat; 2013 Sep; 23(9):1239-45. PubMed ID: 23865465
[TBL] [Abstract][Full Text] [Related]
27. Optimization of 5,6,7,8-tetrahydropyrido[4,3-d]pyrimidines to generate a highly selective PI3Kδ inhibitor.
Hamajima T; Takahashi F; Kato K; Sugano Y; Yamaki S; Suzuki D; Moritomo A; Kubo S; Nakamura K; Yamagami K; Yokoo K; Fukahori H
Bioorg Med Chem; 2019 Mar; 27(6):1056-1064. PubMed ID: 30755348
[TBL] [Abstract][Full Text] [Related]
28. Design, synthesis, and biological evaluation of potent and selective amidino bicyclic factor Xa inhibitors.
Han Q; Dominguez C; Stouten PF; Park JM; Duffy DE; Galemmo RA; Rossi KA; Alexander RS; Smallwood AM; Wong PC; Wright MM; Luettgen JM; Knabb RM; Wexler RR
J Med Chem; 2000 Nov; 43(23):4398-415. PubMed ID: 11087565
[TBL] [Abstract][Full Text] [Related]
29. Probing the 'bipolar' nature of the carbonic anhydrase active site: aromatic sulfonamides containing 1,3-oxazol-5-yl moiety as picomolar inhibitors of cytosolic CA I and CA II isoforms.
Krasavin M; Korsakov M; Dorogov M; Tuccinardi T; Dedeoglu N; Supuran CT
Eur J Med Chem; 2015 Aug; 101():334-47. PubMed ID: 26160114
[TBL] [Abstract][Full Text] [Related]
30. Indazole- and indole-5-carboxamides: selective and reversible monoamine oxidase B inhibitors with subnanomolar potency.
Tzvetkov NT; Hinz S; Küppers P; Gastreich M; Müller CE
J Med Chem; 2014 Aug; 57(15):6679-703. PubMed ID: 24955776
[TBL] [Abstract][Full Text] [Related]
31. Discovery of 5-Azaindazole (GNE-955) as a Potent Pan-Pim Inhibitor with Optimized Bioavailability.
Wang X; Kolesnikov A; Tay S; Chan G; Chao Q; Do S; Drummond J; Ebens AJ; Liu N; Ly J; Harstad E; Hu H; Moffat J; Munugalavadla V; Murray J; Slaga D; Tsui V; Volgraf M; Wallweber H; Chang JH
J Med Chem; 2017 May; 60(10):4458-4473. PubMed ID: 28445037
[TBL] [Abstract][Full Text] [Related]
32. Discovery of methylsulfonyl indazoles as potent and orally active respiratory syncytial Virus(RSV) fusion inhibitors.
Feng S; Li C; Chen D; Zheng X; Yun H; Gao L; Shen HC
Eur J Med Chem; 2017 Sep; 138():1147-1157. PubMed ID: 28772235
[TBL] [Abstract][Full Text] [Related]
33. A Multicentre, Randomized, Double-Blind, Placebo-Controlled, Crossover Study To Investigate the Efficacy, Safety, Tolerability, and Pharmacokinetics of Repeat Doses of Inhaled Nemiralisib in Adults with Persistent, Uncontrolled Asthma.
Khindri S; Cahn A; Begg M; Montembault M; Leemereise C; Cui Y; Hogg A; Wajdner H; Yang S; Robertson J; Hamblin JN; Ludwig-Sengpiel A; Kornmann O; Hessel EM
J Pharmacol Exp Ther; 2018 Dec; 367(3):405-413. PubMed ID: 30217958
[TBL] [Abstract][Full Text] [Related]
34. Potent nonpeptide antagonists of the bradykinin B1 receptor: structure-activity relationship studies with novel diaminochroman carboxamides.
Biswas K; Li A; Chen JJ; D'Amico DC; Fotsch C; Han N; Human J; Liu Q; Norman MH; Riahi B; Yuan C; Suzuki H; Mareska DA; Zhan J; Clarke DE; Toro A; Groneberg RD; Burgess LE; Lester-Zeiner D; Biddlecome G; Manning BH; Arik L; Dong H; Huang M; Kamassah A; Loeloff R; Sun H; Hsieh FY; Kumar G; Ng GY; Hungate RW; Askew BC; Johnson E
J Med Chem; 2007 May; 50(9):2200-12. PubMed ID: 17408249
[TBL] [Abstract][Full Text] [Related]
35. Discovery of a 3-(4-Pyrimidinyl) Indazole (MLi-2), an Orally Available and Selective Leucine-Rich Repeat Kinase 2 (LRRK2) Inhibitor that Reduces Brain Kinase Activity.
Scott JD; DeMong DE; Greshock TJ; Basu K; Dai X; Harris J; Hruza A; Li SW; Lin SI; Liu H; Macala MK; Hu Z; Mei H; Zhang H; Walsh P; Poirier M; Shi ZC; Xiao L; Agnihotri G; Baptista MA; Columbus J; Fell MJ; Hyde LA; Kuvelkar R; Lin Y; Mirescu C; Morrow JA; Yin Z; Zhang X; Zhou X; Chang RK; Embrey MW; Sanders JM; Tiscia HE; Drolet RE; Kern JT; Sur SM; Renger JJ; Bilodeau MT; Kennedy ME; Parker EM; Stamford AW; Nargund R; McCauley JA; Miller MW
J Med Chem; 2017 Apr; 60(7):2983-2992. PubMed ID: 28245354
[TBL] [Abstract][Full Text] [Related]
36. Discovery of a Novel Inhaled PI3Kδ Inhibitor for the Treatment of Respiratory Diseases.
Erra M; Taltavull J; Bernal FJ; Caturla JF; Carrascal M; Pagès L; Mir M; Espinosa S; Gràcia J; Domínguez M; Sabaté M; Paris S; Maldonado M; Hernández B; Bravo M; Calama E; Miralpeix M; Lehner MD; Calbet M
J Med Chem; 2018 Nov; 61(21):9551-9567. PubMed ID: 30351000
[TBL] [Abstract][Full Text] [Related]
37. Biphenylsulfonamide endothelin receptor antagonists. 4. Discovery of N-[[2'-[[(4,5-dimethyl-3-isoxazolyl)amino]sulfonyl]-4-(2-oxazolyl)[1,1'-biphenyl]- 2-yl]methyl]-N,3,3-trimethylbutanamide (BMS-207940), a highly potent and orally active ET(A) selective antagonist.
Murugesan N; Gu Z; Spergel S; Young M; Chen P; Mathur A; Leith L; Hermsmeier M; Liu EC; Zhang R; Bird E; Waldron T; Marino A; Koplowitz B; Humphreys WG; Chong S; Morrison RA; Webb ML; Moreland S; Trippodo N; Barrish JC
J Med Chem; 2003 Jan; 46(1):125-37. PubMed ID: 12502366
[TBL] [Abstract][Full Text] [Related]
38. Discovery of (S)-2-amino-N-(5-(6-chloro-5-(3-methylphenylsulfonamido)pyridin-3-yl)-4-methylthiazol-2-yl)-3-methylbutanamide (CHMFL-PI3KD-317) as a potent and selective phosphoinositide 3-kinase delta (PI3Kδ) inhibitor.
Liang X; Li F; Chen C; Jiang Z; Wang A; Liu X; Ge J; Hu Z; Yu K; Wang W; Zou F; Liu Q; Wang B; Wang L; Zhang S; Wang Y; Liu Q; Liu J
Eur J Med Chem; 2018 Aug; 156():831-846. PubMed ID: 30053721
[TBL] [Abstract][Full Text] [Related]
39. 5-Aryl-4-carboxamide-1,3-oxazoles: potent and selective GSK-3 inhibitors.
Gentile G; Merlo G; Pozzan A; Bernasconi G; Bax B; Bamborough P; Bridges A; Carter P; Neu M; Yao G; Brough C; Cutler G; Coffin A; Belyanskaya S
Bioorg Med Chem Lett; 2012 Mar; 22(5):1989-94. PubMed ID: 22310227
[TBL] [Abstract][Full Text] [Related]
40. Synthesis and biological evaluation of N-(7-indazolyl)benzenesulfonamide derivatives as potent cell cycle inhibitors.
Bouissane L; El Kazzouli S; Léonce S; Pfeiffer B; Rakib EM; Khouili M; Guillaumet G
Bioorg Med Chem; 2006 Feb; 14(4):1078-88. PubMed ID: 16274996
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
